Trimetazidine Dihydrochloride is a metabolic agent used primarily to improve heart muscle efficiency in patients with chronic coronary artery disease and other cardiac conditions. In Hong Kong, it is available only by prescription and is marketed as a 20 mg capsule. The drug belongs to the “Heart & Blood Pressure” therapeutic class and works by altering the way heart cells generate energy, especially under conditions of limited oxygen supply.
Trimetazidine selectively inhibits the enzyme 3-ketoacyl-CoA thiolase, a key step in fatty-acid β-oxidation. By partially blocking fatty-acid breakdown, the heart muscle shifts its energy production toward glucose oxidation, which requires less oxygen per unit of ATP generated. This metabolic shift helps maintain cardiac contractility during episodes of reduced blood flow (ischemia) and can lessen chest-pain (angina) episodes.
Trimetazidine is approved in many jurisdictions for the symptomatic treatment of stable angina pectoris and for improving exercise tolerance in patients with chronic coronary artery disease. In Hong Kong, the Department of Health aligns with these indications, allowing physicians to prescribe it as an adjunct to standard anti-anginal therapy (e.g., beta-blockers, calcium-channel blockers, nitrates).
These symptoms are usually mild and transient; they often resolve without dose modification.
If any of these occur, patients should seek immediate medical attention.
Patients should disclose all prescription medicines, over-the-counter products, supplements, and herbal remedies to their healthcare provider before initiating trimetazidine.
Routine follow-up is recommended to assess symptom control and to monitor for side effects, especially in the first few weeks of therapy. Specific checks may include:
This article provides educational information about trimetazidine dihydrochloride and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, you may travel with a prescription-validated supply of trimetazidine. Keep the medication in its original packaging, carry a copy of the prescription, and be aware that some countries require a doctor’s note for cardiovascular drugs.
Trimetazidine is listed on the World Anti-Doping Agency (WADA) Prohibited List under the “Hormone and Metabolic Modulators” category. Athletes subject to WADA testing should avoid the drug unless granted a Therapeutic Use Exemption (TUE).
In Hong Kong, the 20 mg capsule often bears the imprint “20 MG” followed by a manufacturer code. The exact imprint can vary by supplier; always verify the label matches your prescription.
Yes, trimetazidine is marketed as a generic medication in Hong Kong, typically supplied by multiple local pharmaceutical companies under the same 20 mg capsule formulation.
Traditional agents such as beta-blockers or nitrates lower heart workload or dilate blood vessels. Trimetazidine, by contrast, improves the efficiency of the heart’s energy use without directly affecting heart rate or blood pressure.
Generally, yes. Trimetazidine does not have a significant impact on blood pressure, but clinicians monitor for additive effects if combined with drugs that also lower blood pressure.
Contact your healthcare provider promptly. Tremors may indicate an extrapyramidal reaction, and the physician may adjust the dose or discontinue the medication.
Mild hepatic impairment does not typically require dose adjustment, but clinicians should monitor liver function periodically and adjust therapy if abnormalities develop.
Food has minimal impact on trimetazidine absorption; however, taking the capsule consistently with or without meals helps maintain stable blood levels.
Because it can enhance cellular energy efficiency, trimetazidine may provide an unfair performance advantage, leading to its inclusion on anti-doping prohibited lists.
